Used upon waking, this new medical device (Biosymtec Monitor™) will be able to noninvasively detect developing respiratory and non-respiratory infections up to two days before symptoms, permitting early medical intervention.
The Biosymtec Monitor will provide an immediate report to the user or caretaker and a 50-day graph of readings (Temperature and PEF) on mobile devices using a proprietary graph template.
The Biosymtec Monitor advanced model will have all of the functions and features of the previous model, but will also read other presymptomatic signs including HR, SpO2, and EKG. EKG readings will be compared by an algorithm to the separately acquired HR.
Studies conducted in Hong Kong, Tianjin* and Pennsylvania produced very encouraging results, using Biosymtec Medical's proprietary algorithm. Sensitivity 96.7%
*Tianjin Haihe Hospital
The Research Team, seeking pre-symptomatic signs of infection, focused its efforts on the large COPD, asthma and CHF patient-population markets. Joseph E. Johnson III, Biochemist
John Beiswenger, Design Engineer
James A. Wilson, MD
Joseph E. Johnson III, Biochemist
Biosymtec Medical and SMT Manufacturing Group will design, prototype and produce this new concept in medical devices through pilot production, suitable for clinical and/or market research studies, after which it will be handed off to an exclusive licensee.
To communicate with
John Beiswenger, President and CEO, please use the form on the right.